Formation of Nrg1-NRE25 and Nrg1-Rim101-NRE42 protein-DNA complexes in vitro as assessed by EMSA and interaction of Nrg1 and Rim101 in vitro as assessed by affinity chromatography. (A) Nrg1 binds to NRE25 in vitro. Bacterially expressed MBP-Nrg1 was affinity purified and incubated with a radiolabeled double-stranded oligonucleotide containing NRE25 (5′-CCATAAATAAAAGGGTTCTCTTGCC-3′) prior to electrophoresis on a nondenaturing 6% polyacrylamide gel. The reactions of lanes 4 to 11 contained equivalent amounts of MBP-Nrg1; the reactions of lanes 5 to 7 contained increasing amounts of a nonlabeled NRE25-containing double-stranded oligonucleotide as specific competitor DNA; and the reactions of lanes 8 to 10 contained increasing amounts of a nonlabeled mutant NRE25-containing double-stranded oligonucleotide as a nonspecific competitor (the wild-type sequence 5′-AGGGT-3′ [indicated in boldface type in the sequence given above] was changed to 5′-CTGTA-3′). The reaction of lane 1 contained no protein, and the reaction of lane 11 contained bacterially expressed MBP. The reactions of lanes 2 and 3 contained 5- and 2.5-fold of the amount of MBP-Nrg1 present in the reaction of lane 4. (B) Rim101(1-289) does not interact with the NRE25 site, and MBP-Nrg1 does not interact with the NRE22D site. An EMSA was performed with bacterially expressed Rim101(1-289) present in the soluble fraction of a crude cell lysate (lanes 2 and 4) or affinity-purified bacterially expressed MBP-Nrg1 (lanes 6 and 8) that had been incubated with a radiolabeled oligonucleotide containing NRE22D (Fig. ) (lanes 2 and 8) or NRE25 (lanes 4 and 6). The reactions of lanes 1, 3, 5, and 7 contained probe only. (C) An Nrg1-Rim101-DNA complex forms in vitro with NRE42 but not with NRE42m-2 or NRE42m-1. Bacterially expressed MBP-Nrg1 (lanes 2, 4, 6 to 8, and 12 to 14) or bacterially expressed Rim101(1-289) (lanes 3, 4, and 9 to 14) was incubated with a radiolabeled oligonucleotide containing NRE42 (see Materials and Methods) (lanes 1 to 4), NRE42m-2 (5′-CCATAAATAAAAGGGTTCTCTTGCCTAGAAAAAATAAAAAGGCC-3′ [the mutation is in boldface type]) (lanes 5 to 14, upper panel) or NRE42m-1 (see Materials and Methods) (lanes 5 to 14, lower panel). The reactions of lanes 1 and 5 contained no protein. The reactions of lanes 6 to 8 and lanes 12 to 14 (upper panel) contained increasing amounts of MBP-Nrg1; the reactions of lanes 9 to 11 and lanes 12 to 14 (lower panel) contained increasing amounts of Rim101(1-289). Only the portions of the autoradiograms representing the protein-DNA complexes are shown. (D) Interaction between Nrg1 and Rim101 in vitro. Western blot analysis with HRP-conjugated anti-HA antibodies of samples from an affinity chromatography experiment (see Materials and Methods) is shown. A lysate from induced bacterial cells expressing MBP (lanes 2 to 6) or MBP-Nrg1 (lanes 10 to 14) was incubated with amylose-Sepharose to prepare an affinity resin to capture Rim101 from a yeast cell lysate. The following samples were analyzed: an aliquot of uninduced bacterial cells (U, lanes 1 and 9) and an aliquot of the soluble fraction of a lysate prepared from induced bacterial cells (I, lanes 2 and 10) that contained a vector for expression of MBP (lanes 1 and 2) or MBP-Nrg1 (lanes 9 and 10); an aliquot of a flowthrough fraction after the bacterial lysate-resin (amylose-Sepharose) mixture had been loaded into a column (FT, lanes 3 and 11); an aliquot of a wash fraction from the columns after a lysate prepared from yeast cells expressing Rim101(1-531).3HA had been run through the columns (W, lanes 4 and 12); aliquots of resin-bound protein that had been eluted with maltose (E1 and E2, lanes 5, 6, 13, and 14); an aliquot of the lysate prepared from yeast cells expressing Rim101(1-531).3HA (lanes 7 and 15) or Rim101 (lanes 8 and 16). The asterisks on the left denote bacterial proteins that cross-reacted with the anti-HA antibody; the position of Rim101(1-531).3HA is denoted on the right. (E) The filter of panel C was stripped and reprobed with anti-MBP antibodies as the primary antibody and an HRP-conjugated secondary antibody. Lanes 1 through 8 correspond to lanes 2, 3, 5, 6, 10, 11, 13, and 14, respectively, of panel D.